Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Profectus BioSciences, specialized in development of therapeutic and preventive vaccines, has received a $5.4m grant under the Partnerships for Biodefense RFA by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH.
Subscribe to our email newsletter
The funds will be used for the preclinical development of m102.4, an antibody indicated as a post-exposure prophylactic against Nipah or Hendra virus infection, that can lead to respiratory and encephalitis disease.
M102.4 is a fully human antibody that potently neutralizes all available NiV and HeV isolates in vitro and provides post-exposure protection in several animal models for NiV and HeV infection.
M102.4 was first identified at the Uniformed Services University and the National Cancer Institute.